

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL			
OMB Number:	3235-0104		
Estimated average burden			
nours per respons	se 0.5		

#### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Fillit of Type Kesponses)								
Silberstein David S.		2. Date of Event Requiring Statement (Month/Day/Year) 06/10/2020		3. Issuer Name and Ticker or Trading Symbol Lantern Pharma Inc. [LTRN]				
(Last) (First) (Middle) 124 BYTE DRIVE	00/10/2			4. Relationship of Issuer	, ,		5. If Amendment, Date Original Filed(Month/Day/Year)	
(Street)				(Check _X_ DirectorOfficer (give titl below)	all applicable)  = X_ 10% Owne  Other (specification)	Applicable I	6. Individual or Joint/Group Filing(Check Applicable Line) X Form filed by One Reporting Person	
FREDERICK,, MD 21702				below)	below)		ed by More than One Reporting Person	
(City) (State) (Zip)		Table I - Non-Derivative Securities Beneficially Owned						
1.Title of Security (Instr. 4)		2. Amount of Securities Beneficially Owned (Instr. 4)		ned		4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Common Stock		1,	1,044,000 (1) (2)		I	See Explanation of Responses. (2)		
Reminder: Report on a separate line for each class  Persons who respondences the form distributed to the separate line for each class and the separate line for each class are separate line for each class and the separate line for each class are separate line for e	ond to the c splays a cui	collection or rrently val	of information	on contained in t trol number.		·		
1. Title of Derivative Security (Instr. 4)  2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion	5. Ownership Form of Derivative Security: Direct	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	(D) or Indirect (I) (Instr. 5)		
Stock Options	(3)	(3)	Common Stock	5,096 (1) (3)	\$ 1.03 <del>(1)</del>	D		

### **Reporting Owners**

Panarting Owner Name	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Silberstein David S. 124 BYTE DRIVE FREDERICK,, MD 21702	X	X			

## **Signatures**

,	/s/ David S. Silberstein	06/10/2020
	**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) In connection with the Issuer's initial public offering ("IPO"), the Issuer intends to effect a 1.74-for-1 stock split on its outstanding common stock, which will become effective immediately before the closing of the Issuer's IPO ("Stock Split"). The share amounts and the price reflect the anticipated Stock Split.
  - The securities beneficially owned by the Reporting Person consists of 1,044,000 shares of common stock held of record by Biological Mimetics, Inc. ("BMI"). Dr.
- (2) Silberstein is a director of BMI and shares voting and investment control with respect to shares held by BMI. Because of the relationship between Dr. Silberstein and BMI, Dr. Silberstein may be deemed to beneficially own the shares held directly by BMI. Dr. Silberstein disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- (3) The securities beneficially owned by the Reporting Person consists of 5,096 shares of common stock subject to options exercisable within 60 days.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.